Moderna has been granted a patent for variant RNA polymerases that enhance transcription efficiency and reduce the production of double-stranded RNA contaminants and run-on transcripts during in vitro transcription reactions. The patent specifically claims a T7 RNA polymerase variant with a modified amino acid sequence at position S43, which retains RNA polymerase activity. GlobalData’s report on Moderna gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Moderna, mRNA delivery lipid nanoparticles was a key innovation area identified from patents. Moderna's grant share as of September 2023 was 23%. Grant share is based on the ratio of number of grants to total number of patents.
Variant rna polymerases with increased transcription efficiency and reduced contaminants
A recently granted patent (Publication Number: US11767548B2) discloses a T7 ribonucleic acid (RNA) polymerase variant with modified amino acid sequences. The variant has at least 95% identity to the amino acid sequence of SEQ ID NO: 1 and includes an amino acid substitution at position S43. This modified T7 RNA polymerase variant retains RNA polymerase activity.
The patent also covers a composition or kit that includes the RNA polymerase variant mentioned in claim 1, along with an optional in vitro transcription (IVT) reagent. This composition or kit can be used in various applications related to RNA polymerase activity.
Claim 3 specifies that the amino acid substitution at position S43 can be selected from a group of amino acids, including alanine, isoleucine, leucine, methionine, lysine, glutamine, glutamate, and arginine. Claim 4 further narrows down the substitution to alanine (S43A).
The T7 RNA polymerase variant described in claim 1 can also have an amino acid sequence with at least 98% identity to SEQ ID NO:1, as mentioned in claim 5. Additionally, claim 6 states that the RNA polymerase variant can have the amino acid sequence of SEQ ID NO: 2.
Another embodiment of the T7 RNA polymerase variant is described in claim 7, which has an amino acid sequence with at least 95% identity to SEQ ID NO: 1 and includes an alanine substitution at position 43. This variant also retains RNA polymerase activity. Claim 8 specifies that this variant comprises the amino acid sequence of SEQ ID NO: 2.
Overall, this granted patent discloses various T7 RNA polymerase variants with modified amino acid sequences, which retain RNA polymerase activity. The patent also covers compositions or kits containing these variants, along with optional IVT reagents. These variants can find applications in various fields related to RNA polymerase activity.
To know more about GlobalData’s detailed insights on Moderna, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
